One of the first anti-FAP drugs, the anti-FAP antibody Sibrotuzumab (also known as F19 and BIBH 1) exhibited a good safety profile in patients with FAP-positive advanced or metastatic cancers in a Phase I trial (Scott et al., 2003). This evidence concerns the gene FAP and metastatic malignant neoplasm.